Biblio

Filters: Author is Passweg, Jakob [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Drozd-Sokolowska J, Gras L, Zinger N, Zahrani MAl, Passweg J, Byrne J, Ho A, Huang X-J, Kröger N, Mayer J, et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022.

Maffini E, Labopin M, Kröger N, Finke J, Stelljes M, Schroeder T, Einsele H, Tischer J, Bornhäuser M, Bethge W, et al. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2024.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen--A Report From the Acute Leukemia Worki. J Clin Oncol. 2013.

Christopeit M, Labopin M, Gorin N-C, Saraceni F, Passweg J, Forcade E, Maertens J, van Lint MTeresa, Bosi A, Niederwieser D, et al. Allogeneic Stem Cell Transplantation following Relapse post Autologous Stem Cell Transplantation in adult patients with Acute Myeloid Leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. Am J Hematol. 2018.

Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.

Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBc, Kröger N, Mohty M, Galeano S, Okamoto S, et al. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.

B

Saccardi R, Putter H, Eikema D-J, Busto MPaula, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FAyuketang, Baldomero H, et al. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023.

C

Infanti L, Holbro A, Passweg J, Bolliger D, Tsakiris DA, Merki R, Plattner A, Tappe D, Irsch J, Lin J-S, et al. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days. Transfusion. 2019.

Gratwohl A, Passweg J, Baldomero H, Orchard K, Kröger N, Snowden JA. Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit. Br J Haematol. 2021.

Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, Borne Pvon dem, Snowden JA, et al. Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024.

Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kröger N, Moiseev I, Penack O, Salooja N, Schoemans H, et al. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study. Bone Marrow Transplant. 2023.

D

Mauramo M, Grolimund P, Egli A, Passweg J, Halter J, Waltimo T. Dissociations of oral foci of infections with infectious complications and survival after haematopoietic stem cell transplantation. PLoS One. 2019;14(12):e0225099.

F

Raj K, Eikema D-J, McLornan DP, Olavarria E, Blok H-J, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, et al. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.

G

Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Cermak J, Dinmohamed AG, Eeltink C, Eggmann S, et al. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.

I

Polverelli N, Bonneville EF, de Wreede LC, Koster L, Kröger NMartin, Schroeder T, de Latour RPeffault, Passweg J, Sockel K, Broers AEC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024.

Dalle IAbou, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, et al. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023.

Kuster S, Stampf S, Gerber B, Baettig V, Weisser M, Gerull S, Medinger M, Passweg J, Schanz U, Garzoni C, et al. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation: A Swiss Transplant Cohort Study. Transpl Infect Dis. 2018:e12981.

Medinger M, Heim D, Gerull S, Halter J, Krenger W, Buser A, Lengerke C, Bucher C, Passweg J. Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Leuk Res. 2016;47:22-25.

L

Garderet L, Gras L, Koster L, de Wreede L, Montserrat R, Vincent L, Fenk R, Karunanithi K, Deeren D, Kaufmann M, et al. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow . Haematologica. 2024.

M

Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, Cornelissen JJ, Salmenniemi U, Yakoub-Agha I, Reményi P, et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2023.

Dertschnig S, Passweg J, Bucher C, Medinger M, Tzankov A. Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation. Cell Immunol. 2023;388-389:104719.

Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socié G, Medinger M, Passweg J, Teshima T, et al. Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant Cell Ther. 2022.

Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, et al. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.

N

Medinger M, Lengerke C, Passweg J. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer Genomics Proteomics. 2016;13(5):317-329.

O

Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, et al. Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Pa. Bone Marrow Transplant. 2021.

Pages